Genetic Warfarin Dosing Tables Versus Algorithms

被引:98
作者
Finkelman, Brian S. [1 ,2 ]
Gage, Brian F. [4 ]
Johnson, Julie A. [5 ,6 ]
Brensinger, Colleen M. [1 ,2 ]
Kimmel, Stephen E. [1 ,2 ,3 ]
机构
[1] Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA
[2] Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA
[3] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA
[4] Washington Univ, Dept Internal Med, St Louis, MO USA
[5] Univ Florida, Coll Pharm, Dept Pharmacotherapy & Translat Res, Gainesville, FL USA
[6] Univ Florida, Ctr Pharmacogenom, Gainesville, FL USA
基金
美国国家卫生研究院;
关键词
coumarins; dose prediction; dosing algorithms; FDA label; genetic tables; pharmacogenetics; warfarin; K EPOXIDE REDUCTASE; AFRICAN-AMERICANS; VITAMIN-K; CYTOCHROME P4502C9; DOSAGE REQUIREMENTS; DOSE REQUIREMENTS; CLINICAL FACTORS; CYP2C9; GENOTYPE; PHARMACOGENETICS; ANTICOAGULATION;
D O I
10.1016/j.jacc.2010.08.643
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives The aim of this study was to compare the accuracy of genetic tables and formal pharmacogenetic algorithms for warfarin dosing. Background Pharmacogenetic algorithms based on regression equations can predict warfarin dose, but they require detailed mathematical calculations. A simpler alternative, recently added to the warfarin label by the U. S. Food and Drug Administration, is to use genotype-stratified tables to estimate warfarin dose. This table may potentially increase the use of pharmacogenetic warfarin dosing in clinical practice; however, its accuracy has not been quantified. Methods A retrospective cohort study of 1,378 patients from 3 anticoagulation centers was conducted. Inclusion criteria were stable therapeutic warfarin dose and complete genetic and clinical data. Five dose prediction methods were compared: 2 methods using only clinical information (empiric 5 mg/day dosing and a formal clinical algorithm), 2 genetic tables (the new warfarin label table and a table based on mean dose stratified by genotype), and 1 formal pharmacogenetic algorithm, using both clinical and genetic information. For each method, the proportion of patients whose predicted doses were within 20% of their actual therapeutic doses was determined. Dosing methods were compared using McNemar's chi-square test. Results Warfarin dose prediction was significantly more accurate (all p < 0.001) with the pharmacogenetic algorithm (52%) than with all other methods: empiric dosing (37%; odds ratio [OR]: 2.2), clinical algorithm (39%; OR: 2.2), warfarin label (43%; OR: 1.8), and genotype mean dose table (44%; OR: 1.9). Conclusions Although genetic tables predicted warfarin dose better than empiric dosing, formal pharmacogenetic algorithms were the most accurate. (J Am Coll Cardiol 2011;57:612-8) (C) 2011 by the American College of Cardiology Foundation
引用
收藏
页码:612 / 618
页数:7
相关论文
共 39 条
  • [1] Patient-specific factors predictive of warfarin dosage requirements
    Absher, RK
    Moore, ME
    Parker, MH
    [J]. ANNALS OF PHARMACOTHERAPY, 2002, 36 (10) : 1512 - 1517
  • [2] Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation
    Anderson, Jeffrey L.
    Horne, Benjamin D.
    Stevens, Scott M.
    Grove, Amanda S.
    Barton, Stephanie
    Nicholas, Zachery P.
    Kahn, Samera F. S.
    May, Heidi T.
    Samuelson, Kent M.
    Muhlestein, Joseph B.
    Carlquist, John F.
    [J]. CIRCULATION, 2007, 116 (22) : 2563 - 2570
  • [3] Pharmacology and management of the vitamin K antagonists
    Ansell, Jack
    Hirsh, Jack
    Hylek, Elaine
    Jacobson, Alan
    Crowther, Mark
    Palareti, Gualtiero
    [J]. CHEST, 2008, 133 (06) : 160S - 198S
  • [4] Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P4502C9 gene polymorphisms on warfarin dose requirements
    Aquilante, CL
    Langaee, TY
    Lopez, LM
    Yarandi, HN
    Tromberg, JS
    Mohuczy, D
    Gaston, KL
    Waddell, CD
    Chirico, MJ
    Johnson, JA
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (04) : 291 - 302
  • [5] Booth SL, 1999, NUTR REV, V57, P288
  • [6] Bristol-Meyers Squibb Company, COUM TABL WARF SOD T
  • [7] CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation:: A prospective randomized controlled study
    Caraco, Y.
    Blotnick, S.
    Muszkat, M.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 (03) : 460 - 470
  • [8] An evaluation of nine genetic variants related to metabolism and mechanism of action of warfarin as applied to stable dose prediction
    Carlquist, John F.
    Horne, Benjamin D.
    Mower, Chrissa
    Park, James
    Huntinghouse, John
    McKinney, Jason T.
    Muhlestein, Joseph B.
    Anderson, Jeffrey L.
    [J]. JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2010, 30 (03) : 358 - 364
  • [9] Genetic and Clinical Predictors of Warfarin Dose Requirements in African Americans
    Cavallari, L. H.
    Langaee, T. Y.
    Momary, K. M.
    Shapiro, N. L.
    Nutescu, E. A.
    Coty, W. A.
    Viana, M. A. G.
    Patel, S. R.
    Johnson, J. A.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 (04) : 459 - 464
  • [10] Cavallari LH, 2009, CURR OPIN MOL THER, V11, P243